Diagnosis and treatment of Friedreich ataxia: A European perspective

Nature Reviews Neurology

Volumn 5, Issue 4, 2009, Pages 222-234

  Schulz, Jörg B ^a   Boesch, Sylvia ^b   Bürk, Katrin ^c   Dürr, Alexandra ^d   Giunti, Paola ^e   Mariotti, Caterina ^f   Pousset, Francoise ^d   Schöls, Ludger ^g   Vankan, Pierre ^h   Pandolfo, Massimo ⁱ  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f DEPARTMENT OF NEUROSURGERY   (Italy)

^g UNIVERSITY OF TÜBINGEN   (Germany)

^h Santhera Pharmaceuticals   (Switzerland)

ⁱ ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCARNITINE; ALPHA TOCOPHEROL; CARNITINE; GENE PRODUCT; IDEBENONE; PLACEBO; PROPOFOL; PROTEIN FXN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UBIDECARENONE; UNCLASSIFIED DRUG; ANTIOXIDANT;

ALPHA TOCOPHEROL DEFICIENCY; ANESTHESIA INDUCTION; APRAXIA; AREFLEXIA; ATAXIA; BLADDER DYSFUNCTION; CARDIOMYOPATHY; CEREBELLUM ATROPHY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; DRUG TREATMENT FAILURE; DYSPHAGIA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FOOT MALFORMATION; FRIEDREICH ATAXIA; GASTROTOMY; GENE FREQUENCY; GENETIC ANALYSIS; GEOGRAPHIC DISTRIBUTION; HEARING IMPAIRMENT; HETEROZYGOSITY; HUMAN; INCIDENCE; LOSS OF FUNCTION MUTATION; MORBIDITY; MUTATIONAL ANALYSIS; NERVE BIOPSY; NEUROIMAGING; NEUROLOGIC EXAMINATION; NOSE FEEDING; NUCLEAR MAGNETIC RESONANCE IMAGING; OCULOMOTOR APRAXIA; PHYSIOTHERAPY; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCOLIOSIS; SEXUAL FUNCTION; SPASTIC ATAXIA; SPEECH THERAPY; SURAL NERVE; VISUAL IMPAIRMENT; DIAGNOSTIC IMAGING; EUROPE; GENETICS; METHODOLOGY; NEUROPHYSIOLOGY; PATHOPHYSIOLOGY; SKELETAL MUSCLE;

ANTIOXIDANTS; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; EUROPE; FRIEDREICH ATAXIA; HUMANS; MUSCLE, SKELETAL; NEUROPHYSIOLOGY;

EID: 67649213875     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2009.26     Document Type: Review

References (99)

1. Campuzano, V. et al. Friedreich's ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271, 1423z1427 (1996).
2. Labuda, M. et al. Unique origin and specific ethnic distribution of the Friedreich ataxia GAA expansion. Neurology 54, 2322-2324 (2000).
3. Cossee, M. et al. Evolution of the Friedreich's ataxia trinucleotide repeat expansion: Founder effect and premutations. Proc. Natl Acad. Sci. USA 94, 7452-7457 (1997).
4. Epplen, C. et al. Differential stability of the (GAA) tract in the Friedreich ataxia (STM7) gene. Hum. Genet. 99, 834-836 (1997).
5. Juvonen, V. et al. Dissecting the epidemiology of a trinucleotide repeat disease - example of FRDA in Finland. Hum. Genet. 110 36-40 (2002).
6. Polo, J. M. et al. Hereditary ataxias and paraplegias in Cantabria, spain. An epidemiological and clinical study. Brain 114, 855-866 (1991).
7. Wintermeyer, P. et al. Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients. NeuroReport 11, 2079-2082 (2000).
8. Werdelin, L. & Keiding, N. Hereditary ataxias: Epidemiological aspects. Neuroepidemiology 9, 321-331 (1990).
9. Skre, H. Friedreich's ataxia in western Norway. Clin. Genet. 7 287-298 (1975).
10. Jonasson, J. et al. evidence for a common spinocerebellar ataxia type 7 (SCA7) founder mutation in Scandinavia. Eur. J. Hum. Genet. 8, 918-922 (2000).
11. Colombo, R. & Carobene, A. Age of the intronic GAA triplet repeat expansion mutation in Friedreich ataxia. Hum. Genet. 106, 455-458 (2000).
12. Richards, M. et al. Tracing european founder lineages in the near Eastern mtDNA pool. Am. J. Hum. Genet. 67, 1251-1276 (2000).
13. Semino, O. et al. The genetic legacy of Paleolithic Homo sapiens sapiens in extant Europeans: A Y chromosome perspective. Science 290, 1155-1159 (2000).
14. Tambets, K. et al. The western and eastern roots of the saami - the story of genetic "outliers" told by mitochondrial DNA and Y chromosomes. Am. J. Hum. Genet. 74, 661-682 (2004).
15. Montermini, L. et al. The Friedreich ataxia GAA triplet repeat: premutation and normal alleles. Hum. Mol. Genet. 6, 1261-1266 (1997).
16. Harding, A. E. Friedreich's ataxia: A clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 104, 589-620 (1981).
17. Fahey, M. C. et al. Vestibular, saccadic and fixation abnormalities in genetically confirmed Friedreich ataxia. Brain 131, 1035-1045 (2008).
18. Givre, S. J. et al. Visual loss and recovery in a patient with Friedreich ataxia. J. Neuroophthalmol. 20, 229-233 (2000).
19. Ell, J. et al. Neuro-otological abnormalities in Friedreich's ataxia. J. Neurol. Neurosurg. Psychiatry 47, 26-32 (1984).
20. Rance, G. et al. Speech perception ability in individuals with Friedreich ataxia. Brain 131, 2002-2012 (2008).
21. Trouillas, P. et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J. Neurol. Sci. 145, 205-211 (1997).
22. Subramony, S. H. et al. Measuring Friedreich ataxia: Interrater reliability of a neurologic rating scale. Neurology 64, 1261-1262 (2005).
23. Fahey, M. C. et al. How is disease progress in Friedreich's ataxia best measured? A study of four rating scales. J. Neurol. Neurosurg. Psychiatry 78, 411-413 (2007).
24. Schmitz-Hübsch, T. et al. Scale for the assessment and rating of ataxia: Development of a new clinical scale. Neurology 66 1717-1720 (2006).
25. Lynch, D. R. et al. Measuring Friedreich ataxia: Complementary features of examination and performance measures. Neurology 66 1711-1716 (2006).
26. Dürr, A. et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N. Engl. J. Med. 335, 1169-1175 (1996).
27. Montermini, L. et al. Phenotypic variability in Friedreich ataxia: role of the associated GAA triplet repeat expansion. Ann. Neurol. 41, 675-682 (1997).
28. Ulku, A. et al. Friedreich's ataxia: A clinical review of 20 childhood cases. Acta Neurol. Scand. 77, 493-497 (1988).
29. Alikasifoglu, M. et al. Clinical and genetic correlate in childhood onset Friedreich ataxia. Neuropediatrics 30, 72-76 (1999).
30. Coppola, G. et al. Why do some Friedreich's ataxia patients retain tendon reflexes? A clinical, neurophysiological and molecular study. J. Neurol. 246, 353-357 (1999).
31. Hirai, T. et al. Neurological findings, neurophysiological examinations, and sural nerve biopsy in a case of Friedreich ataxia [Japanese]. Rinsho Shinkeigaku 46, 485-490 (2006).
32. Santoro, L. et al. Relation between trinucleotide GAA repeat length and sensory neuropathy in Friedreich's ataxia. J. Neurol. Neurosurg. Psychiatry 66, 93-96 (1999).
33. Muller-Felber, W. et al. The clinical spectrum of Friedreich's ataxia in German families showing linkage to the FRDA locus on chromosome 9. Clin. Invest. 71, 109-114 (1993).
34. Santiago-Perez, S. et al. A neurophysiological study of the alterations to the central and peripheral nervous systems in Friedreich's ataxia [spanish]. Rev. Neurol. 44, 193-197 (2007).
35. Santoro, L. et al. Influence of GAA expansion size and disease duration on central nervous system impairment in Friedreich's ataxia: contribution to the understanding of the pathophysiology of the disease. Clin. Neurophysiol. 111, 1023-1030 (2000).
36. Claus, D. et al. Central motor conduction in degenerative ataxic disorders: A magnetic stimulation study. J. Neurol. Neurosurg. Psychiatry 51, 790-795 (1988).
37. Mondelli, M. et al. Motor evoked potentials by magnetic stimulation in hereditary and sporadic ataxia. Electromyogr. Clin. Neurophysiol. 35, 415-424 (1995).
38. Lopez-Diaz-de-Leon, E. et al. Auditory neuropathy in Friedreich ataxia. A report of two cases. Int. J. Pediatr. Otorhinolaryngol. 67, 641-648 (2003).
39. Mascalchi, M. et al. Friedreich's ataxia: MR findings involving the cervical portion of the spinal cord. AJR Am. J. Roentgenol. 163, 187-191 (1994).
40. Della Nave, R. et al. Brain structural damage in Friedreich's ataxia. J. Neurol. Neurosurg. Psychiatry 79, 82-85 (2008).
41. Casazza, F. & Morpurgo, M. The varying evolution of Friedreich's ataxia cardiomyopathy. Am. J. Cardiol. 77, 895-898 (1996).
42. Meyer, C. et al. Cardiomyopathy in Friedreich's ataxia - assessment by cardiac MRI. Mov. Disord. 22, 1615-1622 (2007).
43. Kawai, C. et al. Heart disease in Friedreich's ataxia: Observation of a case for half a century. Jpn. Circ. J. 64, 229-236 (2000).
44. Allard, P. et al. Pathomechanics and management of scoliosis in Friedreich ataxia patients: Preliminary report. Can. J. Neurol. Sci. 7, 383-388 (1980).
45. Cady, R. B. & Bobechko, W. P. Incidence, natural history, and treatment of scoliosis in Friedreich's ataxia. J. Pediatr. Orthop. 4, 673-676 (1984).
46. Labelle, H. et al. Natural history of scoliosis in Friedreich's ataxia. J. Bone Joint Surg. Am. 68, 564-572 (1986).
47. Milbrandt, T. A. et al. Friedreich's ataxia and scoliosis: The experience at two institutions. J. Pediatr. Orthop. 28, 234-238 (2008).
48. Beauchamp, M. et al. Natural history of muscle weakness in Friedreich's ataxia and its relation to loss of ambulation. Clin. Orthop. Relat. Res. 311, 270-275 (1995).
49. Moseley, M. L. et al. Incidence of dominant spinocerebellar and Friedreich triplet repeats among 361 ataxia families. Neurology 51, 1666-1671 (1998).
50. Puccio, H. & Koenig, M. Friedreich ataxia: A paradigm for mitochondrial diseases. Curr. Opin. Genet. Dev. 12, 272-277 (2002).
51. Lodi, R. et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann. Neurol. 49, 590-596 (2001).
52. Hart, P. E. et al. Antioxidant treatment of patients with Friedreich ataxia: Four-year follow-up. Arch. Neurol. 62, 621-626 (2005).
53. Rustin, P. et al. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: A preliminary study. Lancet 354, 477-479 (1999).
54. Hausse, A. O. et al. Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart 87, 346-349 (2002).
55. Buyse, G. et al. Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring. Neurology 60 1679-1681 (2003).
56. Mariotti, C. et al. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 60 1676-1679 (2003).
57. Ribai, P. et al. Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up. Arch. Neurol. 64, 558-564 (2007).
58. Pineda, M. et al. Idebenone treatment in paediatric and adult patients with Friedreich ataxia: Long-term follow-up. Eur. J. Paediatr. Neurol. 12, 470-475 (2008).
59. Schöls, L. et al. Idebenone in patients with Friedreich ataxia. Neurosci. Lett. 306, 169-172 (2001).
60. Arnold, P. et al. Expanding view of phenotype and oxidative stress in Friedreich's ataxia patients with and without idebenone. Schweiz. Arch. Neurol. Psychiatr. 157, 169-175 (2006).
61. Artuch, R. et al. Friedreich's ataxia: Idebenone treatment in early stage patients. Neuropediatrics 33, 190-193 (2002).
62. Rustin, P. et al. Heart hypertrophy and function are improved by idebenone in Friedreich's ataxia. Free Radic. Res. 36, 467-469 (2002).
63. Di Prospero, N. A. et al. Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia. Arch. Neurol. 64, 803-808 (2007).
64. Di Prospero, N. A. et al. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: A randomised, placebo-controlled trial. Lancet Neurol. 6, 878-886 (2007).
65. Schols, L. et al. L-carnitine and creatine in Friedreich's ataxia. A randomized, placebo-controlled crossover trial. J. Neural Transm. 112, 789-796 (2005).
66. Sorbi, S. et al. Double-blind, crossover, placebo-controlled clinical trial with L-acetylcarnitine in patients with degenerative cerebellar ataxia. Clin. Neuropharmacol. 23, 114-118 (2000).
67. Miller, E. R. 3rd et al. Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med. 142, 37-46 (2005).
68. Li, K. et al. Iron-dependent regulation of frataxin expression: implications for treatment of Friedreich ataxia. Hum. Mol. Genet. 17, 2265-2273 (2008).
69. Boddaert, N. et al. selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 110, 401-408 (2007).
70. Sohn, Y. S. et al. Redistribution of accumulated cell iron: A modality of chelation with therapeutic implications. Blood 111 1690-1699 (2008).
71. Boesch, S. et al. Friedreich's ataxia: Clinical pilot trial with recombinant human erythropoietin. Ann. Neurol. 62, 521-524 (2007).
72. Herman, D. et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat. Chem. Biol. 2, 551-558 (2006).
73. Rai, M. et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS ONE 3, e1958 (2008).
74. Maring, J. R. & Croarkin, E. Presentation and progression of Friedreich ataxia and implications for physical therapist examination. Phys. Ther. 87, 1687-1696 (2007).
75. American Physical therapy Association. Guide to Physical Therapist Practice, 2nd edn (American Physical Therapy Association, Alexandria, 2001).
76. Delatycki, M. B. et al. Surgery for equinovarus deformity in Friedreich's ataxia improves mobility and independence. Clin. Orthop. Relat. Res. 430, 138-141 (2005).
77. Harris-Love, M. O. et al. Rehabilitation management of Friedreich ataxia: Lower extremity force-control variability and gait performance. Neurorehabil. Neural Repair 18, 117-124 (2004).
78. Goulipian, C. et al. Orthopedic shoes improve gait in Friedreich's ataxia: A clinical and quantified case study. Eur. J. Phys. Rehabil. Med. 44, 93-98 (2008).
79. Ben Smail, D. et al. Intrathecal baclofen in the treatment of painful, disabling spasms in Friedreich's ataxia. Mov. Disord. 20, 758-759 (2005).
80. Cardoso, E. S. et al. Botulinum toxin type A for the treatment of the spastic equinus foot in cerebral palsy. Pediatr. Neurol. 34 106-109 (2006).
81. Bateni, H. et al. Can use of walkers or canes impede lateral compensatory stepping movements? Gait Posture 20, 74-83 (2004).
82. Fillyaw, M. J. & Ades, P. A. Endurance exercise training in Friedreich ataxia. Arch. Phys. Med. Rehabil. 70, 786-788 (1989).
83. Yorkston, K. M. et al. The effect of rate control on the intelligibility and naturalness of dysarthric speech. J. Speech Hear. Disord. 55, 550-560 (1990).
84. Sapir, S. et al. Effects of intensive voice treatment (the Lee Silverman Voice Treatment [LSVT]) on ataxic dysarthria: A case study. Am. J. Speech Lang. Pathol. 12, 387-399 (2003).
85. Ramig, L. O. et al. Intensive voice treatment (LSVT) for patients with Parkinson's disease: A 2 year follow up. J. Neurol. Neurosurg. Psychiatry 71, 493-498 (2001).
86. Yorkston, K. M. et al. Extended communication samples of augmented communicators. I: A comparison of individualized versus standard single-word vocabularies. J. Speech Hear. Disord. 55, 217-224 (1990).
87. Fox, C. M. et al. The science and practice of LSVT/LOUD: Neural plasticity-principled approach to treating individuals with Parkinson disease and other neurological disorders. Semin. Speech Lang. 27, 283-299 (2006).
88. Corben, L. A. et al. Towards an understanding of cognitive function in Friedreich ataxia. Brain Res. Bull. 70, 197-202 (2006).
89. White, M. et al. Neuropsychologic and neuropsychiatric characteristics of patients with Friedreich's ataxia. Acta Neurol. Scand. 102, 222-226 (2000).
90. Wessel, K. et al. Double-blind crossover study with levorotatory form of hydroxytryptophan in patients with degenerative cerebellar diseases. Arch. Neurol. 52, 451-455 (1995).
91. Wilson, C. L. et al. Quality of life in Friedreich ataxia: What clinical, social and demographic factors are important? Eur. J. Neurol. 14, 1040-1047 (2007).
92. D'Ambrosio, R. et al. Disability and quality of life in hereditary ataxias: A self-administered postal questionnaire. Int. Disabil. Stud. 9, 10-14 (1987).
93. Levent, K. et al. Anaesthesia for Friedreich's ataxia. Case report. Minerva Anestesiol. 66, 657-660 (2000).
94. Schmitt, H. J. et al. Rocuronium for muscle relaxation in two children with Friedreich's ataxia. Br. J. Anaesth. 92, 592-596 (2004).
95. Kam, P. C. & Cardone, D. Propofol infusion syndrome. Anaesthesia 62, 690-701 (2007).
96. Short, T. G. & Young, Y. Toxicity of intravenous anaesthetics. Best Pract. Res. Clin. Anaesthesiol. 17, 77-89 (2003).
97. Bruner, J. P. & Yeast, J. D. Pregnancy associated with Friedreich ataxia. Obstet. Gynecol. 76, 976-977 (1990).
98. Fogel, B. L. & Perlman, S. Clinical features and molecular genetics of autosomal recessive cerebellar ataxias. Lancet Neurol. 6, 245-257 (2007).
99. Mukerji, M. et al. Molecular analysis of Friedreich's ataxia locus in the Indian population. Acta Neurol. Scand. 102, 227-229 (2000).